Cerebain Biotech Announces Business Relocation into the Heart of Orange County, California

DALLAS--()--Cerebain Biotech (OTCQB: CBBT) today announced that it is relocating its corporate headquarters from Dallas, Texas into the heart of Orange County in Costa Mesa, California. The decision to relocate was driven by the Company’s plan to seek FDA approval for its medical device for the treatment of Alzheimer’s and Dementia.

“This move allows us to take advantage of Southern California's strong talent pool and cost-effective environment to continue to build our novel, high-value medical device,” said Eric Clemons, President and CEO of Cerebain. We want to be at the center of an ecosystem that shares our aspirations. Southern California attracts a diverse, technologically-fluent workforce focused on solving challenges for the world. We are excited to bring our headquarters to this dynamic and creative area.”

Cerebain Biotech has been considering the composition and location of its headquarters for more than a year. The Company began its formal review in July 2015, with a list of a number of potential locations. Costa Mesa was selected after a careful evaluation of its location in Southern California, the business ecosystem, talent, long-term costs, quality of life for employees, connections with the world and proximity to other important company assets.

About Cerebain Biotech Corp.

Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Contacts

Cerebain Biotech Corp.
Mr. Alan Klitenic, 888-430-2221
info@cerebain.com

Contacts

Cerebain Biotech Corp.
Mr. Alan Klitenic, 888-430-2221
info@cerebain.com